Editorial
Management of unstable angina: what role intervention, ask the RITA-3 trialists?
| The first 150 words of the full text of this article appear below. |
Unstable
angina usually results from the rupture of an atheromatous plaque
within the coronary circulation, which provides a stimulus for platelet
deposition and thrombosis.1 If the thrombus is
subocclusive it produces intense regional ischaemia, expressed
clinically as unstable angina, and there is an ill defined risk of
progression to thrombotic coronary occlusion and myocardial infarction.
Chest pain is inevitable and treatment with opiates should not be
delayed. Nitrates and
blockers are usually sufficient to correct
myocardial ischaemia but dihydropyridine calcium antagonists (nifedipine, amlodipine) should be avoided, particularly in patients who are not taking
blockers.2
Because unstable angina is a thrombotic syndrome, treatment with
antithrombotic drugs can reduce the risk of myocardial infarction and
death. Thrombolytic therapy is unhelpful3 but three
randomised trials have confirmed the benefits of aspirin for improving
early prognosis.4-6 In one trial, unfractionated heparin
was shown to have a similar beneficial effect, although there was no
clear
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
